Russ Conroy

Treatment with (Z)-endoxifen yielded no changes in hematological safety tests among patients enrolled on the phase 2 KARISMA-Endoxifen study.

Extended lymphadenectomy did not improve DFS or OS, and led to a higher incidence of perioperative morbidity and mortality.

Updated OS findings from the PERLA trial showed continued success with dostarlimab plus chemotherapy in patients with advanced non–small cell lung cancer.

Patients who start smoking cessation treatment after cancer diagnosis are found to have higher rates of survival.

IMA203 achieved high response rates in melanoma, with confirmed ORR of 54% in cutaneous and 60% in uveal melanoma.

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.

Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of 20.2 months versus 15.9 months.

The 2-THE-TOP trial showed improved survival with Temodar, TTFields and Keytruda in glioblastoma patients compared to controls.

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.